Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zoledronic acid treatment for focal high bone turnover and osteonecrosis
2010-022318-22Phase 4Terminated
- Sponsor
- Maarit Valkealahti / University hospital of Oulu
- Start
- Aug 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of zoledronic acid in osteonecrosis and high-turnover renal osteodystrophy, sponsored by Maarit Valkealahti / University hospital of Oulu. Primary endpoint: Study completion at 18 months after zoledronic acid infusion. Started Aug 2010; status: terminated.
02
Drugs
zoledronic acid
03
Conditions
osteonecrosishigh-turnover renal osteodystrophy
Beyond the preview
Go deeper on 2010-022318-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-022318-22.